BofA Sees Limited Damage from Novartis (NVS)’ Pelacarsen Miss While Citi Looks Towards Ionis (IONS)
Novartis' pelacarsen failed a Phase 3 trial, but BofA sees limited downside, maintaining a Buy rating and $185 target. Novartis has other Phase 3 readouts expected in 2026. Ionis, which discovered pelacarsen, is expected to see less than 5% downside, according to Citi. Novartis reported Q2 2026 sales of $14.41B, up 3% YoY.
How this was made
The 30-second read
Why it matters
The trial failure is a primary disclosure with material impact on valuation expectations for both Novartis and Ionis.
Market read
First report of a pivotal Phase 3 failure; modest valuation impact but important for pipeline outlook.
What to watch
Potential competitive advances in Lp(a) therapies from other firms could further pressure Novartis.
Background
Novartis reported Q2 2026 sales of $14.41B and reaffirmed low‑single‑digit growth guidance.
Ticker impact
Novartis' Phase 3 pelacarsen trial failed to meet its primary endpoint, lowering Lp(a) but not reducing cardiovascular events.
Modest downside pressure, likely 1‑3% decline.
Failure of a late‑stage asset reduces near‑term pipeline upside but overall valuation impact is limited per BofA.
Ionis, licensor of pelacarsen, faces less than 5% immediate downside after the trial failure.
Minor price movement, likely under 1% change.
Market had already priced limited exposure; trial result confirms expectations.
Market effects
Biotech sector may see slight caution on Lp(a) programs, but broader pipeline focus remains.
European and US pharma markets see limited ripple.
Limited, confined to investors in Novartis and Ionis.
Counterpoint
If subsequent Phase 3 readouts underperform, the valuation impact could be larger than BofA estimates.
Key entities
- companyNovartis AG
Swiss pharma giant, ticker NVS.
- companyIonis Pharmaceuticals
Biotech licensor of pelacarsen, ticker IONS.
